Makers of the favored weight problems therapies Wegovy and Zepbound are chopping costs for folks with out insurance coverage.
Danish drugmaker Novo Nordisk stated Wednesday that it’s going to drop costs 23% for all doses of Wegovy. The brand new month-to-month worth of $499, down from $650, takes impact instantly.
Novo stated the brand new pricing is obtainable to each the uninsured and individuals who have insurance coverage that doesn’t cowl the weight-loss medication.
Final week, Eli Lilly stated it will minimize the month-to-month worth of its starter dose of Zepbound to $349. The U.S. drugmaker is also making bigger doses accessible for $499 by way of its self-pay program.
Sufferers begin taking the injectable medication at smaller dose ranges after which enhance the quantity over time.
The worth cuts come as provides enhance. The U.S. Meals and Drug Administration has moved each medication off its checklist of medicines in scarcity. The company has stated compounding pharmacies and different entities which have been allowed to make off-brand, cheaper copies of the medication throughout the scarcity must wind down manufacturing.
Wegovy and Zepbound are a part of a GLP-1 class of therapies that has proven unprecedented outcomes for serving to folks shed weight by lowering urge for food and boosting emotions of fullness. Gross sales of the medication have soared.
The Related Press Well being and Science Division receives help from the Howard Hughes Medical Institute’s Science and Academic Media Group and the Robert Wooden Johnson Basis. The AP is solely answerable for all content material.
Initially Printed:
